



PAINSCRIPT™

Patient Care, Anywhere.

Med-eXpert System

Scientific Validation


Studied In Nine Government Funded Programs
Published in Multiple Peer-Reviewed Journals

Confidential and Proprietary

Med-eXpert Scientific Validation

Summary of Nine Government Funded Programs

- More than 98% satisfaction among caregivers
- 97% satisfaction in patients with schizophrenia
- 95% medication adherence rate in patients with schizophrenia
- 94% medication adherence rate in patients with heart disease
- 96% protocol adherence rate in patients with heart disease
- 92% medication and protocol adherence rates in patients with diabetes
- HbA1c reduced by 18.5% in three months, and 89.5% medication adherence rates in HIV+, drug abusing, mentally ill, near-homeless patients
- 90% medication adherence rate in senior citizens with diabetes, heart failure, and fifth or sixth grade education levels



PainScript Solutions consistently achieve medication and/or care plan adherence rates of 90% or more across multiple chronic disease states. All trial data is peer-reviewed and published in clinical journal articles.

Confidential and Proprietary



Outcomes Research Using Real-Time Communications

Government Funded Research Programs Using Med-eXpert/Med-eMonitor

Confidential and Proprietary

Disease State	Academic Center	Funding Source	# of Programs	# of Patients	Duration of Research	Medication Adherence Results	Care Plan Adherence Results	Presentations and Publications
HIV+ with drug abuse and severe mental illness	University of California, San Francisco	SBIR/STTR	1	76	Six (6) months	89.5%	N/A	2008 International Association of Physicians in AIDS Care (IAPAC), and submitted for publication
Stroke prevention using Coumadin (Warfarin) and automated lottery system - Phase 1	University of Pennsylvania	PA Tobacco Settlement, Aetna Foundation NHLBI	Phase 1	20	Six (6) months	In first 20 patients, adherence increased from 78% to 97.7%	Out of range INRs decreased from 35% to 12%	Multiple lay publications and insurance company publications. Recent submission to Journal of American Medical Association (JAMA)
Stroke prevention using Coumadin (Warfarin) and automated lottery system-Phase 2	University of Pennsylvania	PA Tobacco Settlement, Aetna Foundation NHLBI	Phase 2	100	Six (6) months	In first 20 patients, adherence increased from 78% to 97.7%	Out of range INRs decreased from 35% to 12%	Multiple lay publications and insurance company publications. Recent submission to Journal of American Medical Association (JAMA)

Confidential and Proprietary

Disease State	Academic Center	Funding Source	# of Programs	# of Patients	Duration of Research	Medication Adherence Results	Care Plan Adherence Results	Presentations and Publications
Stroke prevention using Coumadin (Warfarin) and automated lottery system - Phase 3	University of Pennsylvania	PA Tobacco Settlement, Aetna Foundation NHLBI	Phase 3	268	Six (6) months	In first 20 patients, adherence increased from 78% to 97.7%	Out of range INRs decreased from 35% to 12%	Multiple lay publications and insurance company publications. Recent submission to Journal of American Medical Association (JAMA)
Schizophrenia in "Wounded Warriors"	Baltimore Veterans Hospital	SBIR/STTR	1	22	Three (3) months	The Med-eMonitor System™ provided for compliance enhancement with medications and protocols.	Ease of central evaluation by treating professionals, additional education, and reduced on-site evaluation	Feasibility of Using the Med-eMonitor System in Monitoring and Enhancing Research Protocol Compliance and Health Status in Schizophrenia," Drug Information Journal, 37 (281-289), 2003
Schizophrenia - Phase 1	University of Texas Health Science Center San Antonio	NIMH	Phase 1	20	One (1) year	94%	N/A	"The Med-eMonitor™ for improving adherence to oral medication in schizophrenia", Bendle S, Velligan DI, et. al: Schizophrenia Bulletin, 31 (2): 519, 2005

Disease State	Academic Center	Funding Source	# of Programs	# of Patients	Duration of Research	Medication Adherence Results	Care Plan Adherence Results	Presentations and Publications
Schizophrenia - Phase 2	University of Texas Health Science Center San Antonio	NIMH	Phase 2	120	Three (3) years	95% in the first 69 patients in the two intervention groups in Phase 2	N/A	International Congress of Schizophrenia Research 2005; "Intervention to Improve Adherence to Anti-psychotic Medication", Velligan, DI, Weiden, PJ: Psychiatric Times, August 2006, Vol XXIII, No. 9; <i>The Clinical Handbook of Schizophrenia</i>
Congestive Heart Failure in a Veteran Population	Wayne State University, Detroit Veterans Hospital	NIH	1	18	Three (3) months	94%	96%, improved physical quality of life	"Pilot Study of a Web-Based Compliance Monitoring Device For Patients with Congestive Heart Failure," Artinian, N, Harden, J, et. al., Heart & Lung, 2003: 32, 226-233; "Telehealth as a Tool for Enhancing Care for Patients with Cardiovascular Disease" Artinian, N, Journal of Cardiovascular Nursing, Vol. 22, No. 1, pp 25-31, 2007

Disease State	Academic Center	Funding Source	# of Programs	# of Patients	Duration of Research	Medication Adherence Results	Care Plan Adherence Results	Presentations and Publications
Diabetes	St. Vincent/ University of Pennsylvania	Center for Healthy Aging/Federal	1	20	Three (3) months	92%	HbA1c dropped 18.7% (p<.002)	“Remote Monitoring and Management of Rural Diabetic Patients Using a Web-based Medication Adherence/ePRO Monitoring Device™ Faberow, B, Disease Management Congress, 2005
Diabetes with Congestive Heart Failure	XLHealth, a Medicare Advantage Chronic Care Management Company	Medicare/ XLHealth	1	153	One (1) year	90%	92%	Medical Automation Conference, December 2008. Co-presented with XLHealth and the Ninth Annual Populations Health and Disease Management Colloquium, March 2009

Med-eXpert System/Med-eMonitor

Additional Scientific Validation

Schizophrenia - 2006

Stroke prevention - 2012

Stroke prevention - 2008

HIV/AIDS - 2012

Psychiatric illness - 2010

Schizophrenia - 2013

Med-eXpert System/Med-eMonitor

Additional Scientific Validation


Patient care management - 2008

Medicare Demonstration Program Group – “CMS” - 2011

Department of Veteran Affairs – Psychiatric illnesses - 2015

PainScript Observational Trial

- Published in peer-reviewed Research Post and presented at PainWeek 2022
- 55,000 Patient Responses showing statistically significant improvements across 4 key metrics over 12-week observation period



PAINSCRIPT

A TELEHEALTH AND COMPLIANCE (TACT) COMPANY

Dan Cohen, CEO

PainScript Corporation
6218 Georgia Ave NW
#5080

Washington, DC 20011
Phone: (202) 503-4355

Confidential and Proprietary